Capital International Investors Has $116.36 Million Stock Holdings in Qiagen N.V. $QGEN

by · The Markets Daily

Capital International Investors grew its position in Qiagen N.V. (NYSE:QGEN – Free Report) by 11.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,587,505 shares of the company’s stock after purchasing an additional 264,412 shares during the period. Capital International Investors’ holdings in Qiagen were worth $116,361,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Danske Bank A S bought a new stake in shares of Qiagen in the 3rd quarter valued at about $36,000. Smartleaf Asset Management LLC increased its stake in shares of Qiagen by 1,383.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after acquiring an additional 830 shares during the last quarter. Global Retirement Partners LLC increased its stake in shares of Qiagen by 279.9% in the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after acquiring an additional 851 shares during the last quarter. Allworth Financial LP increased its stake in shares of Qiagen by 23.2% in the 3rd quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock valued at $61,000 after acquiring an additional 256 shares during the last quarter. Finally, Advisory Services Network LLC bought a new stake in shares of Qiagen in the 3rd quarter valued at about $64,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Price Performance

NYSE QGEN opened at $36.28 on Tuesday. The business has a 50 day simple moving average of $37.26 and a 200 day simple moving average of $44.31. Qiagen N.V. has a 52-week low of $32.53 and a 52-week high of $57.81. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21. The stock has a market cap of $7.48 billion, a price-to-earnings ratio of 18.95, a PEG ratio of 3.65 and a beta of 0.66.

Qiagen (NYSE:QGEN – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.54. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.The business had revenue of $492.32 million during the quarter, compared to analysts’ expectations of $496.15 million. During the same period in the prior year, the business earned $0.56 EPS. Analysts anticipate that Qiagen N.V. will post 2.43 earnings per share for the current fiscal year.

Qiagen Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th will be paid a dividend of $0.35 per share. This represents a yield of 104.0%. The ex-dividend date of this dividend is Tuesday, July 7th. This is a positive change from Qiagen’s previous annual dividend of $0.26. Qiagen’s dividend payout ratio (DPR) is currently 13.61%.

Analysts Set New Price Targets

QGEN has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lowered their price target on Qiagen from $60.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. Weiss Ratings cut Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 29th. TD Cowen reaffirmed a “hold” rating and issued a $40.00 price target (down from $46.00) on shares of Qiagen in a research note on Thursday, May 7th. Stifel Nicolaus set a $36.00 price target on Qiagen and gave the company a “hold” rating in a research note on Monday, May 18th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $43.00 price target on shares of Qiagen in a research note on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $44.98.

Read Our Latest Analysis on Qiagen

About Qiagen

(Free Report)

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

Read More

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN – Free Report).